Hepatocyte transplantation (HTx) offers a safer, less invasive alternative to orthotopic liver transplantation for inherited metabolic liver diseases, especially in high-risk pediatric patients. Combining HTx with ex vivo gene editing is a promising autologous therapeutic strategy using the patient’s cells. We investigated the feasibility of this approach by applying CRISPR-Cas9 gene knock-out to neonatal mouse hepatocytes and comparing their engraftment potential with that of mature adult cells in the Fah−/− mouse model of hereditary tyrosinemia type I (HT1). Electroporation-mediated gene editing did not significantly impair the ability of neonatal hepatocytes to engraft in vivo. Quantitative histological analysis revealed comparable liver repopulation levels between recipients of gene-edited neonatal cells and adult cells after hepatoxicity-mediated selection, providing a benchmark for electroporation-mediated gene editing in neonatal hepatocytes, and supporting the development of genetically corrected neonatal hepatocyte products as a crucial long-term or bridge-to-transplant therapeutic strategy for pediatric liver disease.
FerreiraCR, CassimanD, BlauN. Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases. Mol Genet Metab, 2019; 127(2):117–121; doi: 10.1016/j.ymgme.2019.04.002
3.
GuilderL, PulaS, PierreG. Metabolic disorders presenting as liver disease. Paediatr Child Health (Oxford), 2017; 27(12):533–539; doi: 10.1016/j.paed.2017.07.007
4.
PeritoER, RollG, DodgeJL, et al.Split liver transplantation and pediatric waitlist mortality in the United States: Potential for improvement. Transplantation, 2019; 103(3):552–557; doi: 10.1097/TP.0000000000002249
5.
BucuvalasJC, AlonsoE, MageeJC, et al.Improving long-term outcomes after liver transplantation in children. Am J Transplant, 2008; 8(12):2506–2513; doi: 10.1111/j.1600-6143.2008.02432.x
6.
HouY, WangX, YangH, et al.Survival and complication of liver transplantation in infants: A systematic review and meta-analysis. Front Pediatr, 2021; 9:628771; doi: 10.3389/fped.2021.628771
7.
YangLS, ShanLL, SaxenaA, et al.Liver transplantation: A systematic review of long-term quality of life. Liver Int, 2014; 34(9):1298–1313; doi: 10.1111/liv.12553
8.
MarshJW, EsquivelCO, MakowkaL, et al.Accidental transplantation of malignant tumor from a donor to multiple recipients. Transplantation, 1987; 44(3):449–450; doi: 10.1097/00007890-198709000-00025
9.
KimJK, CarmodyIC, CohenAJ, et al.Donor transmission of malignant melanoma to a liver graft recipient: Case report and literature review. Clin Transplant, 2009; 23(4):571–574; doi: 10.1111/j.1399-0012.2008.00928.x
10.
ZelinkovaZ, Geurts-GieleI, VerheijJ, et al.Donor-transmitted metastasis of colorectal carcinoma in a transplanted liver. Transpl Int, 2012; 25(1):e10–e15; doi: 10.1111/j.1432-2277.2011.01380.x
11.
LeeK-W, LeeJ-H, ShinSW, et al.Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant, 2007; 16(6):629–637; doi: 10.3727/000000007783465019
12.
BlackfordSJI, NgSS, SegalJM, et al.Validation of current good manufacturing practice compliant human pluripotent stem cell-derived hepatocytes for cell-based therapy. Stem Cells Transl Med, 2019; 8(2):124–137; doi: 10.1002/sctm.18-0084
13.
RathboneT, AtesI, StuartC, et al.Electroporation-mediated delivery of Cas9 ribonucleoproteins and mRNA into freshly isolated primary mouse hepatocytes. J Vis Exp, 2022(184):e63828; doi: 10.3791/63828
14.
BaccaraniU, AdaniGL, SannaA, et al.Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Int, 2005; 18(6):750–754; doi: 10.1111/j.1432-2277.2005.00127.x
15.
AmbrosinoG, VarottoS, StromSC, et al.Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant, 2005; 14(2–3):151–157; doi: 10.3727/000000005783983250
16.
MeyburgJ, DasAM, HoersterF, et al.One liver for four children: First clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation, 2009; 87(5):636–641; doi: 10.1097/TP.0b013e318199936a
17.
TerryC, DhawanA, MitryRR, et al.Cryopreservation of isolated human hepatocytes for transplantation: State of the art. Cryobiology, 2006; 53(2):149–159; doi: 10.1016/j.cryobiol.2006.05.004
18.
ZhongZ, DuJ, ZhuX, et al.Highly efficient conversion of mouse fibroblasts into functional hepatic cells under chemical induction. J Mol Cell Biol, 2024; 15(11):mjad071; doi: 10.1093/jmcb/mjad071
19.
TakahashiK, TanabeK, OhnukiM, et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007; 131(5):861–872; doi: 10.1016/j.cell.2007.11.019
20.
VonadaA, GrompeM. In vivo selection of hepatocytes. Hepatology, 2024; doi: 10.1097/HEP.0000000000001143
21.
ClarkC, PokhrelM, ArthurB, et al.One shock, not one cure: Electroporation reveals disease-specific constraints in hepatocyte gene editing therapy. Biology (Basel), 2025; 14(8):1091; doi: 10.3390/biology14081091
22.
VonadaA, WakefieldL, MartinezM, et al.Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation. Hepatology, 2024; 79(5):1088–1097; doi: 10.1097/HEP.0000000000000631
23.
ZhangK, WanP, WangL, et al.Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases. Cell Stem Cell, 2024; 31(8):1187–1202.e8; doi: 10.1016/j.stem.2024.04.022
24.
PankowiczFP, BarziM, LegrasX, et al.Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun, 2016; 7:12642; doi: 10.1038/ncomms12642
25.
MaC, CaoH, SunZ, et al.CD47 and PD-L1 overexpression in proliferating human hepatocytes attenuated immune responses and ameliorated acute liver injury in mice. Am J Transplant, 2023; 23(12):1832–1844; doi: 10.1016/j.ajt.2023.07.020
26.
VonadaA, TiyaboonchaiA, NygaardS, et al.Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes. Sci Transl Med, 2021; 13(597):eabg3047; doi: 10.1126/scitranslmed.abg3047
27.
ShiB, KeoughE, MatterA, et al.Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J Histochem Cytochem, 2011; 59(8):727–740; doi: 10.1369/0022155411410885
28.
WangJ, DingY, ChongK, et al.Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery. Vaccines (Basel), 2024; 12(10):1148; doi: 10.3390/vaccines12101148
29.
Batista NapotnikT, MiklavcicD. In vitro electroporation detection methods - An overview. Bioelectrochemistry, 2018; 120:166–182; doi: 10.1016/j.bioelechem.2017.12.005
30.
HarrisonRL, ByrneBJ, TungL. Electroporation-mediated gene transfer in cardiac tissue. FEBS Lett, 1998; 435(1):1–5; doi: 10.1016/s0014-5793(98)00987-9
31.
GibsonJ, DhunganaA, PokhrelM, et al.Validation of clinical-grade electroporation systems for CRISPR-Cas9-Mediated gene therapy in primary hepatocytes for the correction of inherited metabolic liver disease. Cells, 2025; 14(10):711; doi: 10.3390/cells14100711
32.
AtesI, StuartC, RathboneT, et al.Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatol Commun, 2024; 8(5):e0424; doi: 10.1097/HC9.0000000000000424
33.
BluhmeE, HenckelE, GramignoliR, et al.Procurement and evaluation of hepatocytes for transplantation from neonatal donors after circulatory death. Cell Transplant, 2022; 31:9636897211069900; doi: 10.1177/09636897211069900
34.
TolosaL, Pareja-IbarsE, DonatoMT, et al.Neonatal livers: A source for the isolation of good-performing hepatocytes for cell transplantation. Cell Transplant, 2014; 23(10):1229–1242; doi: 10.3727/096368913X669743
35.
LeeCA, DhawanA, IansanteV, et al.Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use. Liver Transpl, 2018; 24(3):394–406; doi: 10.1002/lt.25015
36.
OverturfK, Al-DhalimyM, TanguayR, et al.Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet, 1996; 12(3):266–273; doi: 10.1038/ng0396-266
37.
BrinkmanEK, KousholtAN, HarmsenT, et al.Easy quantification of template-directed CRISPR/Cas9 editing. Nucleic Acids Res, 2018; 46(10):e58-e; doi: 10.1093/nar/gky164
38.
DuncanAW, TaylorMH, HickeyRD, et al.The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature, 2010; 467(7316):707–710; doi: 10.1038/nature09414
39.
OldhaferF, BockM, FalkCS, et al.Immunological aspects of liver cell transplantation. World J Transplant, 2016; 6(1):42–53; doi: 10.5500/wjt.v6.i1.42
40.
Le CouteurDG, NguMC, HuntNJ, et al.Liver, ageing and disease. Nat Rev Gastroenterol Hepatol, 2025; 22(10):680–695; doi: 10.1038/s41575-025-01099-z
41.
ForbesSJ, GuptaS, DhawanA. Cell therapy for liver disease: From liver transplantation to cell factory. J Hepatol, 2015; 62(1 Suppl):S157–S69; doi: 10.1016/j.jhep.2015.02.040
42.
BonifaziF, BarbatoF, RavaioliF, et al.Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol, 2020; 11:489; doi: 10.3389/fimmu.2020.00489
43.
AndersonTN, ZarrinparA. Hepatocyte transplantation: Past efforts, current technology, and future expansion of therapeutic potential. J Surg Res, 2018; 226:48–55; doi: 10.1016/j.jss.2018.01.031
44.
SlehriaS, RajvanshiP, ItoY, et al.Hepatic sinusoidal vasodilators improve transplanted cell engraftment and ameliorate microcirculatory perturbations in the liver. Hepatology, 2002; 35(6):1320–1328; doi: 10.1053/jhep.2002.33201
45.
VermaA, ManchelA, MelunisJ, et al.From seeing to simulating: A survey of imaging techniques and spatially-resolved data for developing multiscale computational models of liver regeneration. Front Syst Biol, 2022; 2:917191; doi: 10.3389/fsysb.2022.917191
46.
LucianiA, ParouchevA, SmirnovP, et al.In vivo imaging of transplanted hepatocytes with a 1.5-T clinical MRI system–initial experience in mice. Eur Radiol, 2008; 18(1):59–69; doi: 10.1007/s00330-007-0750-7
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
